<<

. 2
( 2 .)



oia?aiiue e aunieee (oaae. 2).
oioy au iaiiai oaeoi?a ?enea ioiinyony e a?oiia oia-
N?aae iaoeaioia oa?aiaaoe?aneiai i?ioeey e a?oi-
?aiiiai ?enea aicieeiiaaiey aaiiciuo o?iiaicia e
ia aunieiai ?enea aaiiciuo o?iiaicia ioiinyony aieu-
o?iiaiyiaieee. ?aiaiiece?iaaiiua eeeie?aneea en-
iua n einoeuoaie, n oy?aeui ooieoeiiaeuiui eeannii
iuoaiey, i?iaaaaiiua n?aae iiaiaiuo eaoaai?ee iaoe-
na?aa?iie iaainoaoi?iinoe (OA < 28% eee aeeaoaoeii-
aioia, naeaaoaeunoao?o, ?oi IIA nie?a?o ?ene o?iiai-
iay ea?aeiiaoey), ia?oaoaeuiay a?eoiey, eioa?eo iei-
cia aeoaieeo aai e oeacuaa?o ia oaeaniia?aciinou eo
ea?aa, iaeioi?ua iieieiae?aneea ia?aciaaiey (aaaii-
i?eiaiaiey. I?eiaiaiea O?aaieia iicaieyao i?iai-
ea?oeiiia, ?ae iiei?iie ?aeacu, ye?ieeia, ieyeii?i-
aeou yooaeoeaio? e aaciianio? i?ioeeaeoeeo «aaiic-
eeoa?aoeaiua caaieaaaiey). ?anoioa aaiiciuo o?iiai-
iiai o?iiaiyiaieecia» o oa?aiaaoe?aneie a?oiiu
cia ii aaiiui ?acee?iuo aaoi?ia, i?e einoeuoao ainoe-
aieuiuo.
aaea 60%, a i?e i?iaaaaiee i?ioeeaeoe?aneeo ia?i-
i?eyoee n iiiiuu? IIA nie?aeanu ia 60–85%.
A e?oiiii ia?aoia?iaiii ?aiaiiece?iaaiiii
ieaoaai–eiio?iee?oaiii enneaaiaaiee PREVENT 3706
iaoeaioia n aaiiciui o?iiaiyiaieeciii (eiiaeiaoey
o?iiaic aeoaieeo aai, eaai?iay o?iiaiyiaieey, aneii-
oiiaoe?aneay o?iiaiyiaieey i?ieneiaeuiuo aeoaieeo
aai) auee ?aiaiiece?iaaiu ia a?oiio, iieo?a?uo?
aaeoaia?ei 5000 AA/noo e ieaoaai a oa?aiea 14 aiae ia-
ae?aaeenu a oa?aiea 90 aiae. A ?acoeuoaoa auei iiea-
aEUA?UU?
caii, ?oi i?eiaiaiea aaeoaia?eia 5000 AA/noo nie?aao
1. AIU C.e., AIU a.C., NA?IO‚ a.a., iIAOU?IO‚ a.a. iEAEOIO„E? OEOUAI? „AIO-
?anoioo aicieeiiaaiey o?iiaica a 2 ?aca ii n?aaiaie?
OUA. aOOI‚. 1955 „.
n a?oiiie ieaoaai i?e ieceii ?enea ?acaeoey e?iaioa-
2. eEO?AIIO A.A., e?AO·?EAIOIEE N.C. cEAIOIOIAIUI??I?A „AO?EI?: ‚OAIOEIO-
?aiey [13]. OUE O?EIAIAIE?. a?EOIO„E?. 1995. 10. 86–90.
I?e i?iaaaaiee ?ao?iniaeoeaiiai aiaeeca aacu 3. aOUAI?IEIO‚ a.C. i?OI·O?I·OIE? IA„O?IOE ?UA?EE. aAUOE?AOIEA ?AIOIAI-
aaiiuo (enneaaiaaiea PREVENT) iieacaia aunieay yo- ?EE. aOOI‚. 2002
4. aA?AIEA OOU?O„O IO?OI?IO„O OEI?OI ·AA OUOEIE? OO?AIO‚ OA„IAIU ST I
oaeoeaiinou i?eiaiaiey 5000 U/d aaeoaia?eia o 1118
uaE. eOOOEEOIEA ?AIOIAI?EE. e?EIOEAIEA I EU?IIU «a?EOIO„E?».2001. 10.
(30,4%) iaoeaioia n i?e?aieai (eiaaen iannu oaea ai-
5. uIIU?I C.a., E?E?AIIO C.C. a·O?UO?I?E IOIU?OI? IUEIO„UI?IUIOE UA?OEE U
eaa 30 ea/i2 o io??ei e 28,6 ea/i2 o ?aiuei) e o 1226 ?E?U?„E?AOIE? ·OI?I??. aAUOE?AOIEA ?AIOIAI?EE. eIIU–eAUA?·U?„. 2002.
(33,3%) ii?eeuo iaoeaioia (75 eao e noa?oa) ai anao 6. oEIO‚ A.a., aAI?IEI a.C. iEIIEI ‚ O?OUEIIUEIA E IA?AIEE OA?A?IO– OOOUE-
eiia?iuo oi?eao ii n?aaiaie? n a?oiiie ieaoaai, i?e- OU?? A·OIA‚IEE. U. eOO. aA. CAOUE. 2003, 4, 42.
7. oEUUII i.N. eUOUEAEOIO„E? I?O‚E. eA?. O I„I. aOOI‚. 2000. 191–182.
?ai i?eiaiaiea aaeoaia?eia ia nii?iai?aaeinu ?ac-
8. Butchart E.G., Bodnar E. Trombosis, embolism and bliding. London. ICR Pablisher.
aeoeai e?iaioi?eainoe a iaaeo a?oiiao [14].
1992/ 123–172.
Niaeanii iaoei aaiiui, i?e i?eiaiaiee aaeoaia- 9. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) investigators.
?eia a aica 120 IA/ea aaa ?aca a aaiu n oaeu? i?ioe- Effects of dopidogrel in addition to aspirin in patients with acute coronary syndromes
eaeoeee o?iiaica aeoaieeo aai o 40 aieuiuo n NI IIA – III without ST–segment elevation. N.Engl.J.Med. 2001.345, 494.
10. Mehta S., Ysuf S., Peters R and all. Effects of pretreatment with clopidogrel and
coaiaiu? e 4 ooieoeiiaeuiui eeannii oieuei a 2,5%
aspirin fallowed by long–term therapy in patients undergoing percutaneous coronary
neo?aaa eiaei ianoi ?acaeoea i?eciaeia o?iiaica i?i-
intervention: the PCI–CURE study. Lancet. 2001. 358, 527.
eneiaeuiuo aai, inei?iaiiuo o?iiaiyiaieeae eaai?- 11. The Assessment of the Safety and Efficacy of a New Thrombolytc Regimen. (ASSENT)
iie a?oa?ee, a oi a?aiy eae a aiaeiae?iie a?oiia iaoe- – 3 investigators. Efficacy and safety of tenecteplase in comination with enoxaparine,
aioia (41 aieuiie) ia oiia ea?aiey aaia?eiii ec ?an- aboximab or unfractionated heparin: the ASSENT –3 randomised trial in acute myocar-
dial infarction. Lancet. 2001. 358, 605.
?aoa 1500 AA/?an aiaeiae?iua iieacaoaee niioaaono-
12. Nighttingel S.L. Appropriate use of low molecular weight heparins (LMWH)/ JAMA.
aaiii ninoaaeee: o?iiaic i?ieneiaeuiuo aai – 12,2% (5
1993. Vol.270. 1672.
iaoeaioia), OYEA – 7,3% (3 iaoeaioa). 13. Leizorovicz A., Cohen A.T., Turpie A.G.G. et all. Randomized, Placeb0–Controlled Trial
O 12 iaoeaioia n ianoaaeeuiie noaiiea?aeae (n?aa- of Dalteparin fpr the Prevention of Venous Thromboembolism in Acutely III Medical
iee aic?ano 57,5±5,1 eao, 7 io??ei, 5 ?aiuei) a i?i- Patients. Vascular Medicine, 2004.
14. Kucher N., Leizorovicz A., Vaitkus P.T. et all. Efficacy and Safety of Fixed Dalteparin
a?aiio ea?aiey aue aee??ai O?aaiei a aica 8400 IA
in Preventing Venous Thromboembolism Among Obese or Elderly Hospitalized Patients.
aaa ?aca a nooee a oa?aiea 5 aiae: oi?ioea ?acoeuoaou
A Subgroup Analysis of the PREVENT Trial. Arch Intern Med. 2005; 165: 341–345.
(ionoonoaea noaiiea?aeoe?aneeo aieae) auee iieo?aiu o


444 13, 7, 2005

<<

. 2
( 2 .)